Good morning. I'm James Holman from the Washington Post and this is the Daily

202 for Thursday, April 16th. In today's news, President Trump's attempt to enlist business and is pushed to reopen the

economy is off to a rocky start.

As humans stay indoors, wild animals are taking back what was once theirs, and survivors share

what it's like to be alive on the other side of the coronavirus.

But first, the big idea.

In a desperate bid to find treatments for people sickened by COVID-19,

doctors and drug companies have launched for people sickened by COVID-19.

Doctors and drug companies have launched more than 100 human experiments

in the United States alone.

There are more than 500 worldwide.

They're investigating a hodgepodge of experimental drugs, a decades old malaria medicine,

and cutting-edge therapies that have worked for other conditions like HIV or rheumatoid arthritis.

Development of effective treatments would be one of the most significant

milestones in returning to normalcy. But multiple researchers and health experts tell us that the

massive effort is disorganized and scattershot, harming its prospects for success.

Researchers working around the clock describe a lack of a centralized national strategy overlapping efforts, an array of small-scale

trials that will not lead to definitive answers, and no standards for how to prioritize efforts, what data to collect, or how to

share it to get answers faster.

Francis Collins, the Director of the National Institutes of Health, the Nation's largest biomedical research agency,

acknowledged these frustrations yesterday, but he tells us that he has been working behind the scenes

to launch an unprecedented public-private partnership to address these problems.

...